by The generative AI in personalized medicine market study focuses on recent development, competitive scenario and key strategies on top key players along with industry size, share, growth revenue, geographical highlights. It also covers detailed information on segments and sub-segments of industry.
Key Takeaways:
- North America is expected to dominate in the generative AI in personalized medicine market during the forecast period.
- By personalized medicine therapeutics, the pharmaceutical segment is expected to hold a leading position in the generative AI in personalized medicine market.
- By deployment model, the cloud-based segment is expected to carry a significant share of the generative AI in personalized medicine market during the forecast period.
- By end-user, the hospitals and clinics segment shares the maximum CAGR during the projection period.
The market research report on the Generative AI in personalized medicine market provides a comprehensive analysis of various key aspects. It includes the definition, classification, and application of Generative AI in personalized medicine products. The report examines the development trends, competitive landscape, and industrial chain structure within the industry. Furthermore, it presents an overview of the industry, analyzes national policies and planning, and offers insights into the latest market dynamics and opportunities at a global level.
Get a Sample:https://www.precedenceresearch.com/sample/3095
Generative AI in Personalized Medicine Market Report Scope
| Report Coverage | Details |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Personalized Medicine Therapeutics, By Deployment Model, and By End-User |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: Gas Meter Market Size to Garner USD 22.4 Billion by 2032
The report presents the volume and value-based market size for the base year 2022 and forecasts the market’s growth between 2023 and 2032. It estimates market numbers based on product form and application, providing size and forecast for each application segment in both global and regional markets.
Focusing on the global Generative AI in personalized medicine market, the report highlights its status, future forecasts, growth opportunities, key market players, and key market regions such as the United States, Europe, and China. The study aims to present the development of the Generative AI in personalized medicine market by considering factors like Year-on-Year (Y-o-Y) growth, in addition to Compound Annual Growth Rate (CAGR). This approach enables a better understanding of market certainty and the identification of lucrative opportunities.
Regarding production, the report investigates the capacity, production, value, ex-factory price, growth rate, and market share of major manufacturers, regions, and product types. On the consumption side, the report focuses on the regional consumption of Generative AI in personalized medicine products across different countries and applications.
Buyers of the report gain access to verified market figures, including global market size in terms of revenue and volume. The report provides reliable estimations and calculations for global revenue and volume by product type from 2023 to 2032. It also includes accurate figures for production capacity and production by region during the same period.
The research includes product parameters, production processes, cost structures, and data classified by region, technology, and application. Furthermore, it conducts SWOT analysis and investment feasibility studies for new projects.
This in-depth research report offers valuable insights into the Generative AI in personalized medicine market. It employs an objective and fair approach to analyze industry trends, supporting customer competition analysis, development planning, and investment decision-making. The project received support and assistance from technicians and marketing personnel across various links in the industry chain.
The competitive landscape section of the report provides detailed information on Generative AI in personalized medicine market competitors. It includes company overviews, financials, revenue generation, market potential, research and development investments, new market initiatives, global presence, production sites, production capacities, strengths and weaknesses, product launches, product range, and application dominance. However, the data points provided only focus on the companies’ activities related to the Generative AI in personalized medicine market.
Prominent players in the market are expected to face tough competition from new entrants. Key players are targeting acquisitions of startup companies to maintain their dominance. The report
Reasons to Purchase this Report:
- Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
- In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
- Market size in USD million and volume in million units provided for each segment and sub-segment.
- Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
- Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.
Key Players
- Butterfly Network
- Deep Genomics
- Google LLC
- IBM Watson Health
- Microsoft Corporation
- Aidoc
- Insilico Medicine
- PathAI
- Tencent Holdings Ltd.
- Neuralink Corporation
- Johnson & Johnson
Generative AI in Personalized Medicine Market Segmentations
By Personalized Medicine Therapeutics
- Pharmaceutical
- Genomic Medicine
- Devices
By Deployment Model
- On-premise
- Cloud Based
By End-User
- Hospitals and Clinics
- Clinical Research
- Healthcare Organizations
- Diagnostic Centers
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Generative AI in Personalized Medicine Market
5.1. COVID-19 Landscape: Generative AI in Personalized Medicine Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Generative AI in Personalized Medicine Market, By Personalized Medicine Therapeutics
8.1. Generative AI in Personalized Medicine Market, by Personalized Medicine Therapeutics, 2023-2032
8.1.1 Pharmaceutical
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Genomic Medicine
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Devices
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Generative AI in Personalized Medicine Market, By Deployment Model
9.1. Generative AI in Personalized Medicine Market, by Deployment Model, 2023-2032
9.1.1. On-premise
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Cloud Based
9.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Generative AI in Personalized Medicine Market, By End-User
10.1. Generative AI in Personalized Medicine Market, by End-User, 2023-2032
10.1.1. Hospitals and Clinics
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Clinical Research
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Healthcare Organizations
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Diagnostic Centers
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Generative AI in Personalized Medicine Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.1.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.1.3. Market Revenue and Forecast, by End-User (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.1.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.1.5.3. Market Revenue and Forecast, by End-User (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.2.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.2.3. Market Revenue and Forecast, by End-User (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.2.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.2.5.3. Market Revenue and Forecast, by End-User (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.2.6.3. Market Revenue and Forecast, by End-User (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.2.7.3. Market Revenue and Forecast, by End-User (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.3.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.3.3. Market Revenue and Forecast, by End-User (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.3.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.3.5.3. Market Revenue and Forecast, by End-User (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.3.6.3. Market Revenue and Forecast, by End-User (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.3.7.3. Market Revenue and Forecast, by End-User (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.4.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.4.5.3. Market Revenue and Forecast, by End-User (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.4.6.3. Market Revenue and Forecast, by End-User (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.4.7.3. Market Revenue and Forecast, by End-User (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.5.3. Market Revenue and Forecast, by End-User (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.5.4.3. Market Revenue and Forecast, by End-User (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Deployment Model (2020-2032)
11.5.5.3. Market Revenue and Forecast, by End-User (2020-2032)
Chapter 12. Company Profiles
12.1. Butterfly Network
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Deep Genomics
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Google LLC
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. IBM Watson Health
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Microsoft Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Aidoc
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Insilico Medicine
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. PathAI
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Tencent Holdings Ltd.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Neuralink Corporation
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
